These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 23617237)

  • 1. Pioglitazone and bladder cancer: two studies, same database, two answers.
    de Vries F; Zeegers M; Goossens ME
    Br J Clin Pharmacol; 2013 Sep; 76(3):484-5. PubMed ID: 23617237
    [No Abstract]   [Full Text] [Related]  

  • 2. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.
    Mamtani R; Haynes K; Bilker WB; Vaughn DJ; Strom BL; Glanz K; Lewis JD
    J Natl Cancer Inst; 2012 Sep; 104(18):1411-21. PubMed ID: 22878886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
    Tseng CH
    J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
    Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
    Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
    Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
    Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pioglitazone use and risk of bladder cancer in patients with type 2 diabetes: retrospective cohort study using datasets from four European countries.
    Korhonen P; Heintjes EM; Williams R; Hoti F; Christopher S; Majak M; Kool-Houweling L; Strongman H; Linder M; Dolin P; Bahmanyar S
    BMJ; 2016 Aug; 354():i3903. PubMed ID: 27530399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
    Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
    BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examples of how the pharmaceutical industries distort the evidence of drug safety: the case of pioglitazone and the bladder cancer issue.
    Faillie JL; Hillaire-Buys D
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):212-4. PubMed ID: 26617411
    [No Abstract]   [Full Text] [Related]  

  • 9. Pioglitazone use and the risk of bladder cancer.
    Kuo HW; Tiao MM; Ho SC; Yang CY
    Kaohsiung J Med Sci; 2014 Feb; 30(2):94-7. PubMed ID: 24444539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Observational follow-up of the PROactive study: a 6-year update.
    Erdmann E; Song E; Spanheimer R; van Troostenburg de Bruyn AR; Perez A
    Diabetes Obes Metab; 2014 Jan; 16(1):63-74. PubMed ID: 23859428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone use and risk of bladder cancer: population based cohort study.
    Tuccori M; Filion KB; Yin H; Yu OH; Platt RW; Azoulay L
    BMJ; 2016 Mar; 352():i1541. PubMed ID: 27029385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone and bladder cancer: a population-based study of Taiwanese.
    Tseng CH
    Diabetes Care; 2012 Feb; 35(2):278-80. PubMed ID: 22210574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between pioglitazone and urothelial bladder cancer.
    Barbalat Y; Dombrovskiy VY; Weiss RE
    Urology; 2012 Jul; 80(1):1-4. PubMed ID: 22626574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone causing urinary bladder cancer? While waiting for the result of the debate, suggestions for physicians.
    Cagiltay E; Tuncel T; Yönem A; Ozdemir G
    Eur J Intern Med; 2013 Mar; 24(2):e21-2. PubMed ID: 23267737
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
    Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
    Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pioglitazone: No Longer a Worry for Bladder Cancer?
    Chedgy EC; Black PC
    Urology; 2016 May; 91():19-20. PubMed ID: 26892646
    [No Abstract]   [Full Text] [Related]  

  • 17. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
    Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
    Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
    Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
    Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
    He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
    Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone and risk of bladder cancer: clarification of the design of the French study.
    Perez AT
    Diabetologia; 2013 Jan; 56(1):227. PubMed ID: 23135221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.